Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Marcel HAM Fens, Gert Storm & Raymond M Schiffelers. (2010) Tumor vasculature as target for therapeutic intervention. Expert Opinion on Investigational Drugs 19:11, pages 1321-1338.
Read now
Read now
Michelle Head & Michael B Jameson. (2010) The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opinion on Investigational Drugs 19:2, pages 295-304.
Read now
Read now
Articles from other publishers (18)
Gabriela Mazur, Katarzyna Pańczyk-Straszak & Anna Maria Waszkielewicz. (2023) Xanthone Derivatives in the Fight against Glioblastoma and Other Cancers. Applied Sciences 13:5, pages 2897.
Crossref
Crossref
Carla Fernandes, Maria Carraro, João Ribeiro, Joana Araújo, Maria Tiritan & Madalena Pinto. (2019) Synthetic Chiral Derivatives of Xanthones: Biological Activities and Enantioselectivity Studies. Molecules 24:4, pages 791.
Crossref
Crossref
João Ribeiro, Cláudia Veloso, Carla Fernandes, Maria Elizabeth Tiritan & Madalena M. M. Pinto. (2019) Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives. Molecules 24:1, pages 180.
Crossref
Crossref
Zhenlei Jiang, Jie Liu, Fan Zhou, Jianrun Zhang, Zhijun Liu, Chao Zhang & Heru Chen. (2018) One-step Construction of Xanthone Scaffold Assisted by Microwave Irradiation to Optimize the Synthesis of DMXAA. Chemical Research in Chinese Universities 34:6, pages 918-922.
Crossref
Crossref
Jie Liu, Cao Zhang, Huailing Wang, Lei Zhang, Zhenlei Jiang, Jianrun Zhang, Zhijun Liu & Heru Chen. (2018) Incorporation of nitric oxide donor into 1,3-dioxyxanthones leads to synergistic anticancer activity. European Journal of Medicinal Chemistry 151, pages 158-172.
Crossref
Crossref
Jie Liu, Fan Zhou, Lei Zhang, Huailing Wang, Jianrun Zhang, Cao Zhang, Zhenlei Jiang, Yanbing Li, Zhijun Liu & Heru Chen. (2018) DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions. European Journal of Medicinal Chemistry 143, pages 1768-1778.
Crossref
Crossref
Constanze Hantel, Alexandra Ozimek, Regia Lira, Bruno Ragazzon, Carsten Jäckel, Roman Frantsev, Martin Reincke, Jérôme Bertherat, Thomas Mussack & Felix Beuschlein. (2016) TNF alpha signaling is associated with therapeutic responsiveness to vascular disrupting agents in endocrine tumors. Molecular and Cellular Endocrinology 423, pages 87-95.
Crossref
Crossref
Du?an Milanovi?Friederike Braun, Wolfgang Weber, Anca Ligia Grosu, Martin Behe & Gabriele Niedermann. (2012) The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts. BMC Cancer 12:1.
Crossref
Crossref
M. Pons-Salort, B. van der Sanden, A. Juhem, A. Popov & A. Stéphanou. (2012) A Computational Framework to Assess the Efficacy of Cytotoxic Molecules and Vascular Disrupting Agents against Solid Tumours. Mathematical Modelling of Natural Phenomena 7:1, pages 49-77.
Crossref
Crossref
Guru Sonpavde, Cora N Sternberg, Jonathan E Rosenberg, Noah M Hahn, Matthew D Galsky & Nicholas J Vogelzang. (2010) Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet Oncology 11:9, pages 861-870.
Crossref
Crossref
. (2010) Current World Literature. Current Opinion in Oncology 22:2, pages 155-161.
Crossref
Crossref
Suresh S Ramalingam & Chandra P Belani. (2010) Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Current Opinion in Oncology 22:2, pages 79-85.
Crossref
Crossref
Christelle Cl?ment-Duch?ne & Heather Wakelee. (2010) Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review. Journal of Thoracic Oncology 5:1, pages 129-139.
Crossref
Crossref
Yuval Shaked, Paul Nathan, Laura G. M. Daenen & Robert S. Kerbel. 2010. Vascular Disruptive Agents for the Treatment of Cancer. Vascular Disruptive Agents for the Treatment of Cancer
117
134
.
R. Barbara Pedley & Gillian M. Tozer. 2010. Vascular Disruptive Agents for the Treatment of Cancer. Vascular Disruptive Agents for the Treatment of Cancer
49
75
.
Graeme J. Dougherty & David J. Chaplin. 2010. Vascular Disruptive Agents for the Treatment of Cancer. Vascular Disruptive Agents for the Treatment of Cancer
1
27
.
Mukund Seshadri & Michael J Ciesielski. (2009) MRI-Based Characterization of Vascular Disruption by 5,6-Dimethylxanthenone-Acetic Acid in Gliomas. Journal of Cerebral Blood Flow & Metabolism 29:8, pages 1373-1382.
Crossref
Crossref
Shangjin Yang & William A. Denny. (2009) A new short synthesis of 5,6-dimethylxanthenone-4-acetic acid (ASA404, DMXAA). Tetrahedron Letters 50:27, pages 3945-3947.
Crossref
Crossref